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Background: The response of ovarian cancer patients to carboplatin and paclitaxel is variable, necessitating identification of
biomarkers that can reliably predict drug sensitivity and resistance. In this study, we sought to identify dynamically controlled
genes and pathways associated with drug response and its time dependence.
Methods: Gene expression was assessed for 14 days post-treatment with carboplatin or carboplatin–paclitaxel in xenografts from
two ovarian cancer models: platinum-sensitive serous adenocarcinoma-derived OV1002 and a mixed clear cell/endometrioid
carcinoma-derived HOX424 with reduced sensitivity to platinum.
Results: Tumour volume reduction was observed in both xenografts, but more dominantly in OV1002. Upregulated genes in
OV1002 were involved in DNA repair, cell cycle and apoptosis, whereas downregulated genes were involved in oxygen-
consuming metabolic processes and apoptosis control. Carboplatin–paclitaxel triggered a more comprehensive response than
carboplatin only in both xenografts. In HOX424, apoptosis and cell cycle were upregulated, whereas Wnt signalling was inhibited.
Genes downregulated after day 7 from both xenografts were predictive of overall survival. Overrepresented pathways were also
predictive of outcome.
Conclusions: Late expressed genes are prognostic in ovarian tumours in a dynamic manner. This longitudinal gene expression
study further elucidates chemotherapy response in two models, stressing the importance of delayed biomarker detection and
guiding optimal timing of biopsies.
Current standard treatment for ovarian cancer consists of
carboplatin with or without paclitaxel following surgery
(Cannistra, 2004). Although the majority of patients initially
respond to therapy, most eventually relapse whereas others are
resistant to treatment at the outset (International Collaborative
Ovarian Neoplasm Group, 2002). Thus, it is important to
understand and define which patients are likely to be sensitive to
treatment and who have resistant disease. In this study, we
analysed gene expression changes after treatment in two ovarian
cancer models with distinct chemotherapy response profiles over a
period of 14 days. The OV1002 model is derived from high-grade
serous adenocarcinoma and is platinum sensitive, whereas
HOX424 is of clear cell/endometrioid carcinoma origin and has
reduced responsiveness to platinum.
Our emphasis was on pathways rather than individual genes.
Previous studies have evaluated the association of gene expression
directly with outcome in clinical specimens (Helleman et al, 2006;
Tothill et al, 2008; Crijns et al, 2009; Konstantinopoulos et al,
2011) and have predominantly sought to identify candidate genes
that link with outcome. Other studies have evaluated the temporal
impact of platinum on sensitive and resistant ovarian cancer
cells in vitro with a view to identifying resistance mechanisms
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(Li et al, 2007); however, the cisplatin-treated isogenic cell lines
were monitored for a limited period of 24 h. Several genes have
been found differentially expressed in ovarian cancer cell lines
treated with platinum drugs or taxanes (Sherman-Baust et al,
2011). Helleman et al (2010) have used a panel of nine gene sets
associated with platinum resistance to perform pathway analysis.
Knowledge of the molecular mechanisms involved in drug
response is essential to improve therapy and possibly reverse drug
resistance (Shahzad et al, 2009).
The use of human ovarian cancer xenografts allows the analysis
of drug treatment on temporal changes of gene expression in
cancer tissue after treatment, a task not easily undertaken in
patients. Comparison of models that are either chemosensitive or
chemoresistant should help identify gene expression changes that
are associated with response, and some of these genes are likely to
be helpful to predict outcome after treatment. In this study, we
used models with distinct response patterns to carboplatin and
assessed their gene expression profiles after treatment with drugs.
We identified time-related gene clusters and significant pathways
with predictive value within independent clinical data sets.
MATERIALS AND METHODS
Xenografts. The OV1002 and HOX424 models were established
at the Institute of Genetics and Molecular Medicine, University of
Edinburgh, as previously described (Faratian et al, 2011). Adult
female nu/nu mice were implanted subcutaneously with ovarian
tumour fragments in the flanks and allowed to grow to 4–6mm in
diameter (over a period of B2 months). Animals were at least 8
weeks old at the time of experimentation and were maintained in
negative pressure isolators (La Calhene, Cambridge, UK). The
mice were treated with carboplatin (50mg kg 1), carboplatin
(50mg kg 1)þ paclitaxel (10mg kg 1) or were untreated. Drugs
were given as a single injection via the intraperitoneal route in
saline on day 0. Tumour size was measured twice weekly using
calipers and the volume calculated according to the formula
p/6 lengthwidth2. Relative tumour volumes (RTV) were then
calculated for each individual tumour by dividing the tumour
volume on day t (Vt) by the tumour volume on day 0 (V0).
Treated xenografts were harvested on days 1, 2, 4, 7 and 14, and
untreated controls on days 0, 1, 7 and 14. A total of 101 xenografts
were used, with 3–4 biological replicates per time point
(except carboplatin–paclitaxel-treated HOX424 on day 2 that had
2 replicates; Supplementary Table 1, column D). Agreement
between their expression levels was good as measured by the
correlation coefficients (r) among replicates of each condition
(mean r 95% confidence interval 0.987–0.990, Supplementary
Table 1, column E).
Gene expression profiling and analysis. Total RNA was prepared
from 10 to 50mg of frozen tissue on the days of treatment,
preincubated with RNAlater-ICE (Ambion, Austin, TX, USA)
using the miRNeasy Mini kit (Qiagen, Hilden, Germany) and
TissueRuptor (Qiagen) following the manufacturers’ instructions.
The RNA quality was checked by the RNA 6000 Nanoassay on the
Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
All samples were divided into two identical aliquots for
independent labelling and hybridisation. Total RNA for each
sample (0.5mg) was amplified and biotinylated using the Illumina
TotalPrep RNA Amplification Kit (Ambion) according to
manufacturers’ standard procedure. This consists of reverse
transcription with an oligo(dT) primer bearing a T7 promoter
using a reverse transcriptase (RT). The quality and quantity of
cRNA in the samples was checked with an Agilent Bioanalyzer
2100 (Agilent Technologies), samples were diluted to 150 ngml 1
and hybridised to Illumina HT-12 BeadChips in duplicate
(Illumina, San Diego, CA, USA). This Illumina platform was
previously validated by qPCR in a breast cancer-derived xenograft
study (Sims et al., 2012).
Analysis of microarray data. Illumina chips contained 47 323
probes. Expression sets were processed using Bioconductor’s lumi
package (Du et al, 2008). The data set has been deposited to Gene
Expression Omnibus (GEO) with accession number GSE49577.
Bioconductor package limma (Smyth, 2005) was used for
differential expression calculations. Treated samples from days 1,
2, 4, 7 and 14 post-treatment were contrasted to pooled controls in
each cell line. Significant genes had FDR adjusted P-values of
o0.05. Differentially expressed genes were classified as early (days
1–4) and/or late (days 7 and 14), and as either transient (expressed
significantly in one time point) or sustained (expressed signifi-
cantly in at least two time points). Means of log-fold change values
for each time point of differentially expressed genes were
hierarchically clustered using Cluster 3.0 (Eisen et al, 1998) to
identify genes with similar temporal profiles. Heatmaps were
visualised using Bioconductor. Overrepresented KEGG (Kyoto
encyclopedia of genes and genomes) pathways (Kanehisa et al,
2012) were identified using DAVID (Database for Annotation,
Visualisation and Integrated Discovery) (Huang et al, 2009).
Hierarchical clustering and Kaplan–Meier survival analysis.
Two clinical ovarian cancer gene expression data sets from GEO,
GSE9891 (Tothill et al, 2008) and GSE3149 (Bild et al, 2006), were
used to assess the prognostic capacity of dynamically changing
genes in response to treatment (Supplementary Table 2). Clinical
data, such as survival time and censoring information, were
available for both data sets. Our hypothesis was that, if gene sets
play crucial roles in tumour progression, then patients with
different gene expression patterns of such gene sets may also have
different overall survival (OS) and prognosis. For each cluster of
differentially expressed genes from both treatments and models in
our study, the corresponding genes were selected in the two clinical
ovarian cancer data sets. Unsupervised hierarchical clustering was
applied to expression values in the clinical data sets in order to
separate tumour samples based on expression profiles, as described
previously (Liu et al, 2008). The hierarchical clustering was divided
at the highest level to produce two groups of tumour samples
having the most broadly different gene expression profiles.
Kaplan–Meier plots were graphed to visualise the difference in
OS between these groups and, thus, the capacity of the gene set to
discriminate favourable from poor prognosis patients. Log rank
P-values were calculated to assess the statistical significance of the
difference in survival probabilities between the two patient groups.
Using the same methodology, sets of differentially expressed genes
with distinct temporal expression profiles were tested, as well as
genes in selected overrepresented pathways. To mitigate multiple
testing issues, only significant pathways known to be involved in
ovarian cancer were tested. Except where noted, all genes in an
overrepresented pathway that were extant in the clinical data set
(whether they had been differentially expressed in our data set or
not) were used as the gene set.
RESULTS
Treatment with carboplatin or carboplatin-paclitaxel causes a
reduction in tumour growth of ovarian cancer model
xenografts. The effect of carboplatin and carboplatin–paclitaxel
treatment on tumour volume growth was assessed 1, 2, 4, 7, 11 and
14 days post-treatment. Treated xenografts demonstrated an RTV
reduction compared with control samples (Figure 1A). In OV1002
xenografts, both treatments resulted in a clear growth inhibition.
Differences were significant at all time points (Po0.01; Student’s
t-test) with values diverging from day 1. The effect peaked at day 7
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for carboplatin or day 11 for carboplatin–paclitaxel, where RTV
dropped well below one in treated samples. By day 14, the growth
inhibition effect showed signs of reversal. Reduction in RTV was
steady and gradual in both groups, although carboplatin–paclitaxel
had a larger effect than carboplatin at day 7 (P¼ 0.04).
Untreated HOX424 samples grew more slowly (Figure 1A). A
small growth reduction effect due to both treatment types
compared with control was observed, but this was significant
only at days 2–7 (carboplatin, Po.03) or day 4 (carboplatin–
paclitaxel, Po0.001).
Carboplatin dynamically modulates DNA repair, cell cycle and
apoptosis control genes in OV1002 xenografts, but has limited
effect in gene expression of HOX424. In OV1002 xenografts, a
total of 711 genes were differentially expressed mainly late and
transiently after carboplatin treatment (Figures 2A and B). A
complete listing is shown in Supplementary Table 3, and genes
with the largest expression change compared with control are
shown in Supplementary Table 4. Several pathways involved in cell
cycle control were overrepresented within the pool of differentially
expressed genes from all time points, such as cell cycle, DNA
replication and p53 signalling (Table 1A, complete pathway
statistics in Supplementary Table 5). Hierarchical clustering
separated the genes into four main clusters (Figure 1B).
Genes in cluster 1 were mainly upregulated early in treated
samples. Many were implicated in cell cycle regulation and DNA
repair. Cluster 2 contained genes implicated in apoptosis that were
either upregulated or downregulated early and later upregulated.
Genes in cluster 3 were mostly upregulated late in treated samples.
It contained several genes implicated in the cell cycle and p53
signalling pathways, as well as HIF1a and its target MET. Cluster 4
genes were mainly downregulated with late expression. This group
contained several HIF1a targets and genes with anti-apoptotic
activity (Supplementary Table 6). The results suggest that in
OV1002, cell cycle control, DNA repair and pro-apoptotic genes
dominated the early response to carboplatin. From day 7, more cell
cycle regulators and p53 signalling genes were detected.
In HOX424 xenografts, very few differentially expressed genes
were observed upon treatment with carboplatin. Significant genes
are shown in Supplementary Table 3 (complete list) and
Supplementary Table 7 (largest changes).
Carboplatin–paclitaxel treatment has distinct time-related
effects in each ovarian cancer model. In OV1002 xenografts, a
total of 3045 genes were differentially expressed upon carboplatin–
paclitaxel treatment. The majority of differential genes expressed
late and transiently (Figures 2A and B). Genes with the largest
expression change upon treatment are shown in Supplementary
Table 8, and a complete list of differentially expressed genes is
shown in Supplementary Table 3. Cell proliferation and DNA
repair-related pathways such as cell cycle, DNA replication, p53
signalling, nucleotide excision repair, base excision repair, homo-
logous recombination and mismatch repair were overrepresented
within differentially expressed genes (Table 1B, complete pathway
statistics in Supplementary Table 9). Glutathione metabolism was
also significant. Hierarchical clustering separated the genes into
four main clusters (Figure 1B).
Genes in cluster 1 were predominantly upregulated early and
were implicated in cell cycle control, DNA repair, apoptosis, TGFb
and Wnt signalling pathways. Cluster 2 genes were generally
downregulated early in treated samples. This cluster contained
genes implicated in oxidative phosphorylation and citrate cycle,
several HIF1a targets and STAT3, RBL2 and RAB2B. The third
cluster contained genes that were mainly upregulated late in
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Figure 1. Relative tumour volume (RTV) growth with respect to dynamic gene expression patterns. (A) Post-treatment tumour volume relative to
day of treatment (day 0) for the OV1002 and HOX424 xenografts. (B) Mean expression change post-treatment of genes with similar temporal
profiles in carboplatin- and carboplatin–paclitaxel-treated OV1002 and in carboplatin–paclitaxel-treated HOX424 xenografts.
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treated samples. It included several genes implicated in cell cycle
control and p53 signalling and in immune system-related
pathways. Other significant genes were members of MAPK and
ERBB signalling pathways and PARP9 and PARP10. Genes in
cluster 4 were mostly downregulated late and included HIF1a
targets, some of which were implicated in mTOR signalling.
Several heat shock proteins, including several hsp70 species, and
Wnt signalling pathway targets were also detected. Other
significant genes included DYRK1B, ESR1 and H3F3B
(Supplementary Table 6).
In HOX424, there were 510 significant genes with exclusively
late/transient expression patterns that were clustered in four
groups (Figure 1B and Supplementary Table 3). Genes with the
largest expression fold change are shown in Supplementary
Table 10. Overrepresented KEGG pathways included
apoptosis, Wnt signalling and ribosome pathways (Table 1C and
Supplementary Table 9).
Upregulated clusters 1 and 2 were implicated in apoptosis, in
cell cycle regulation and other genes with known cancer
involvement. Downregulated genes in clusters 3 and 4 were
involved in Wnt and MAPK signalling pathways. Other genes in
this cluster included HIF1a, MSH2 and PMS1 (Supplementary
Table 6).
These results suggest distinct modes of response to carboplatin–
paclitaxel treatment in each ovarian cancer model. In OV1002, the
early response was dominated by cell cycle control, DNA repair,
pro-apoptotic genes, TGFb and Wnt signalling pathways, whereas
aerobic metabolic pathways were downregulated. From day 7,
more cell cycle regulators, p53 signalling genes, immune system
related, MAPK and ERBB pathway genes were detected.
In HOX424, the cell cycle and DNA repair response was
limited and late. Instead, several pro-apoptotic genes were
induced, whereas Wnt and MAPK signalling pathways were
downregulated.
The combined treatment instigated a more extensive response
compared with carboplatin alone, judging from the larger count of
differentially expressed genes in both xenografts. In OV1002, there
was significant overlap of responsive genes between treatments,
with 542 genes in common. There was significant overlap among
corresponding upregulated groups, especially among the early
expressed (Figure 2). Most of the differentially expressed genes in
carboplatin-treated xenografts were significant in the combined
treatment also, but EME1 (upregulated early), MYC (upregulated
late), SIPA1, SIAH1, IGFBP3 and ERCC1 (downregulated) were
specific for carboplatin. In carboplatin–paclitaxel-treated OV1002,
there were more significant genes within pathways observed
in carboplatin-treated cells, but also genes of new pathways
altogether (Figure 3).
Dynamic gene expression analysis reveals variation between the
two ovarian models in their response to chemotherapeutic
agents. When treated xenografts were compared with control
samples, more differentially expressed genes were found in
OV1002 than in HOX424 after either treatment. There were 206
genes in common between the two xenografts in the combination
treatment, of which 143 had the same regulation. For instance,
PARP2 and FANCD2 were positively whereas CASP6, MAPK9 and
BNIP3L were negatively regulated in both cell lines. A total of 63
genes had opposite regulation (up/down compared with control).
Some of these were upregulated in OV1002, such as ETS1, RAPH1,
NEK2, MAD2L1, PSMD1, or in HOX424, for instance CAT,
HSPA12A, FASTK and WDR6. Pro-apoptotic TNFRSF1A of the
MAPK pathway and Wnt pathway modulator SENP2 were
upregulated in OV1002, but downregulated in HOX424. Xeno-
grafts differed in the time patterns of gene expression, with the
chemoresistant HOX424 responding 7 days post-treatment,
whereas platinum-sensitive OV1002 demonstrated a more
balanced response across time points.
Dynamically changing genes and overrepresented pathways are
prognostic of outcome in independent data sets. The relation-
ship to clinical outcome in the clinical ovarian cancer data sets
(Supplementary Table 2) was assessed for sets of differentially
expressed genes, both for all genes identified from a condition and
genes clusters. Gene sets from downregulated late clusters in
carboplatin–paclitaxel-treated xenografts were found prognostic of
OS in both data sets (Table 2). Other gene sets, such as upregulated
late and downregulated early clusters, were successful at differ-
entiating prognosis in one data set.
The relationship to clinical outcome was also assessed for
overrepresented pathways. Several overrepresented pathways in the
overall set of differentially expressed genes (leftmost columns in
Table 1) like oocyte meiosis, apoptosis and cell cycle were
prognostic of OS in at least one independent data set. Another
seven pathways including Wnt signalling pathway, nucleotide
excision repair and focal adhesion were significant predictors
(Po0.05) of OS in one of the two independent data sets.
Glutathione metabolism pathway was a significant predictor of
OS in both independent data sets. Although all gene members of
the cell cycle pathway were prognostic of OS in one data set,
subsets of genes found significant in the early upregulated
combined treated OV1002 xenografts were prognostic of OS in
both data sets. Two pathways in late downregulated gene
sets (rightmost columns in Table 1) were prognostic of OS
(Table 2): neurotrophin signalling pathway and b-alanine
metabolism (Figure 4).
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Figure 2. Differential expression analysis of treated OV1002 and
HOX424 xenografts. Venn diagrams of differentially expressed gene
counts in each time point (A) and according to their temporal
characteristics (B) in carboplatin- and carboplatin–taxane-treated
OV1002 and HOX424 cells. Gene expression was analysed in 5 time
points post-treatment (days 1, 2, 4, 7 and 14). Early (late) genes were
differentially expressed in days 1, 2 and 4 (days 7 and 14). Transient
(sustained) were differentially expressed in a single time point (more
than one time point). (C) Venn diagrams of gene overlaps in each
corresponding cluster with similar temporal expression profiles in
carboplatin- and carboplatin–paclitaxel-treated OV1002 cells.
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Table 1. KEGG pathways overrepresented in dynamically changing genes upon treatment with carboplatin or carboplatin taxane in OV1002 and
HOX424 xenografts
A
OV1002 carboplatin
All differentially expressed genes Cluster 1: up early Cluster 2: down/up early Cluster 3: up late Cluster 4: down late
hsa04110: cell cycle
hsa00970: aminoacyl-tRNA
biosynthesis
hsa00240: pyrimidine
metabolism
hsa04115: p53 signalling
pathway
hsa04914: progesterone-
mediated oocyte maturation
hsa04114: oocyte meiosis
hsa00230: purine metabolism
hsa03030: replication
hsa05130: pathogenic
Escherichia coli infection
hsa00970: aminoacyl-tRNA
biosynthesis
hsa04110: cell cycle
hsa00670: one carbon pool by
folate
hsa00240: pyrimidine
metabolism
hsa03030: DNA replication
hsa04612: antigen
processing and presentation
hsa00240: pyrimidine
metabolism
hsa04623: cytosolic DNA-
sensing pathway
hsa04110: cell cycle
hsa04114: oocyte meiosis
hsa04914: progesterone-
mediated oocyte maturation
hsa04115: p53 signalling
pathway
hsa04540: Gap junction
hsa00051: fructose and
mannose metabolism
hsa00240: pyrimidine
metabolism
B
OV1002 carboplatin–paclitaxel
All differentially expressed genes Cluster 1: up early Cluster 2: down early Cluster 3: up late Cluster 4: down late
hsa03010: ribosome
hsa04110: cell cycle
hsa03030: DNA replication
hsa03420: nucleotide excision
repair
hsa04115: p53 signalling
pathway
hsa00970: aminoacyl-tRNA
biosynthesis
hsa00100: steroid biosynthesis
hsa00240: pyrimidine
metabolism
hsa03410: base excision repair
hsa03430: mismatch repair
hsa00250: alanine, aspartate
and glutamate metabolism
hsa03050: proteasome
hsa05130: pathogenic
Escherichia coli infection
hsa00230:Purine metabolism
hsa00520: amino sugar and
nucleotide sugar metabolism
hsa03440: homologous
recombination
hsa00670: one carbon pool by
folate
hsa00270: cysteine and
methionine metabolism
hsa00051: fructose and
mannose metabolism
hsa00052: galactose metabolism
hsa04612: antigen processing
and presentation
hsa00480: glutathione
metabolism
hsa03030: DNA replication
hsa04110: cell cycle
hsa00970: aminoacyl-tRNA
biosynthesis
hsa00240: pyrimidine
metabolism
hsa03410: base excision repair
hsa03420: nucleotide excision
repair
hsa03430: mismatch repair
hsa00230: purine metabolism
hsa00670: one carbon pool by
folate
hsa04115: p53 signalling
pathway
hsa03440: homologous
recombination
hsa00630: glyoxylate and
dicarboxylate metabolism
hsa00250: alanine, aspartate
and glutamate metabolism
hsa04350: TGF-b signalling
pathway
hsa00020: citrate cycle (TCA
cycle)
hsa00190: oxidative
phosphorylation
hsa04142: lysosome
hsa00280: valine, leucine
and isoleucine degradation
hsa05322: systemic lupus
erythematosus
hsa00100: steroid
biosynthesis
hsa04360: axon guidance
hsa03050: proteasome
hsa04110: cell cycle
hsa04114: oocyte meiosis
hsa05130: pathogenic
Escherichia coli infection
hsa05416: viral myocarditis
hsa05330: allograft rejection
hsa04612: antigen
processing and presentation
hsa04914: progesterone-
mediated oocyte maturation
hsa04115: p53 signalling
pathway
hsa05332: graft-versus-host
disease
hsa04514: cell adhesion
molecules (CAMs)
hsa05320: autoimmune
thyroid disease
hsa04144: endocytosis
hsa04940: type I diabetes
mellitus
hsa04810: regulation of
actin cytoskeleton
hsa04672: intestinal immune
network for IgA production
hsa03010: ribosome
hsa03420: nucleotide
excision repair
hsa00051: fructose and
mannose metabolism
hsa00280: valine, leucine
and isoleucine degradation
hsa00520: amino sugar
and nucleotide sugar
metabolism
hsa00561: glycerolipid
metabolism
hsa04722: neurotrophin
signalling pathway
hsa00650: butanoate
metabolism
hsa03040: spliceosome
hsa00410: b-alanine
metabolism
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DISCUSSION
Despite the progress in identification of genes involved in the
development of resistance to platinum- and taxane-based
chemotherapeutic agents, the exact timing of the transcriptional
response post-treatment warrants further research. Two xenograft
models with distinct platinum response profiles were used to
characterise drug-induced gene expression patterns. This long-
itudinal study spanned a 14-day period and allowed the analysis of
gene expression in multiple time points. Such insight in dynamic
expression changes can indicate not only markers associated with
platinum sensitivity or resistance, but also the time they become
detectable. Clinical snapshots cannot provide such a dynamic view
of the transcriptome and may potentially miss informative changes
in expression (Taylor et al, 2010).
The two models displayed distinct transcriptional profiles before
and after treatment. Up to 4 biological replicates were used for each
time point in this study, with high concordance within each
condition. A significant RTV effect was observed in the platinum-
responsive, high-grade OV1002 xenografts. Early upregulated
genes were involved in DNA repair, cell cycle and apoptosis
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Figure 3. Heatmaps of gene sets with significant increased (red) or decreased (green) expression in response to treatment relative to control
samples. (A) Carboplatin-treated OV1002, (B) carboplatin–paclitaxel-treated OV1002 and (C) carboplatin–paclitaxel-treated HOX424 xenografts.
Clusters are annotated with significant overrepresented functions.
C
HOX424 carboplatin–paclitaxel
All differentially expressed genes Cluster 1: up late (day 7) Cluster 2: up late (day 14) Cluster 3: down late (day 7) Cluster 4: down late (day 14)
hsa03010: ribosome
hsa05130: pathogenic
Escherichia coli infection
hsa05210: colorectal cancer
hsa03040: spliceosome
hsa04210: apoptosis
hsa04530: tight junction
hsa04510: focal adhesion
hsa04662: B-cell receptor
signalling pathway
hsa00450: selenoamino acid
metabolism
hsa00510: N-glycan biosynthesis
hsa04310: Wnt signalling
pathway
hsa05416: viral myocarditis
hsa03010: ribosome
hsa00450: selenoamino acid
metabolism
hsa04210: apoptosis
hsa00460: cyanoamino acid
metabolism
hsa00430: taurine and
hypotaurine metabolism
hsa00590: arachidonic acid
metabolism
— hsa03010: ribosome
hsa05130: pathogenic
Escherichia coli infection
hsa04510: focal adhesion
hsa04310: Wnt signalling
pathway
hsa03050: proteasome
hsa03010: ribosome
hsa03040: spliceosome
hsa05210: colorectal cancer
hsa05130: pathogenic
Escherichia coli infection
hsa05211: renal cell carcinoma
hsa04670: leukocyte
transendothelial migration
Abbreviations: IgA¼ immunoglobulin A; KEGG¼Kyoto encyclopedia of genes and genomes; TCA¼ tricarboxylic acid; TGFb¼ transforming growth factor-b; tRNA¼ transfer RNA. Pathways
are shown for the set of all differentially expressed genes (left column) and for gene sets with similar temporal profiles. (A) Carboplatin-treated OV1002, (B) carboplatin–paclitaxel-treated
OV1002 and (C) carboplatin–paclitaxel-treated HOX424.
Table 1. ( Continued )
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regulation, suggesting a driving effect on these pathways
immediately after treatment administration. DNA damage-induced
apoptosis seems to be responsible for the large RTV reduction in
OV1002. In carboplatin–paclitaxel-treated cells, a concurrent
downregulation of oxygen-consuming metabolic processes was
observed, suggesting a reduction in the metabolic rate and a switch
to hypoxic processes. The number of genes was increased in late
time points and included downregulated apoptosis inhibitors and
heat shock proteins. The RTV effect was gradually reduced in late
time points after expression of anti-apoptotic regulators such as
aurora kinases and possibly because of hypoxic adaptation.
Treatment-based upregulation of HIF1a may also be responsible
for the gradual RTV reduction observed after day 7.
Carboplatin uptake triggers activation of DNA repair pathways
and, in case damage is beyond repair, cell cycle arrest and apoptosis
(Galluzzi et al, 2012). In accordance with this, early response in
OV1002 involved DNA repair, cell cycle control and apoptosis
genes, which were upregulated in both treatments, with many more
in the combined. Several gene functions essential for drug
chemosensitivity were observed, providing plausible explanations
for the response to treatment by OV1002 and the gradual change
to chemoresistance. For instance, CHEK1, which activates branches
of MAPK pathway, and CHEK2, shown to convey lethal signals in
response to carboplatin (Damia et al, 2001; Pabla et al, 2008), were
upregulated in treated xenografts. Several PARPs, including
PARP2, PARP6, PARP9 and PARP10, were significant after day
4, potentially influencing the growth rate during late time points.
Downregulation of ERCC1 has been correlated with survival and
responsiveness to platinum treatment in various cancers, including
ovarian (Dabholkar et al, 1992). This gene was downregulated in
carboplatin-treated samples. Early expression of the tumour
suppressor XAF1, which antagonises apoptosis inhibitors
(Plenchette et al, 2007), was observed in carboplatin-treated
xenografts, whereas pro-apoptotic FAS was upregulated in
carboplatin–paclitaxel-treated samples. TRIB3, a pro-apoptotic,
negative regulator of AKT1 and NFkB that is involved in hypoxia
Table 2. Prognostic capacity of gene sets with similar temporal expression profiles in three ovarian cancer data sets (log rank P-values)
Data set Bild et al (2006) Tothill et al (2008)
Data set ID GSE3149 GSE9891
Microarray platform Affymetrix U133A Affymetrix U133 Plus 2
Samples 133 285
Platinum/taxane 243/195
Tumour grade (1/2/3/NA) 3/4/125/1 19/97/164/5
End point OS OS PFS
Gene set Gene set size
All OV1002 carboplatin sets 711 0.0473 0.00292 0.000642
All OV1002 carboplatin/taxane sets 3045 0.128 0.00101 2.88E05
All HOX424 carboplatin/taxane sets 510 0.00931 0.000136 0.000268
OV1002 carboplatin set 1 up early 171 0.421 0.315 0.87
OV1002 carboplatin set 2 down/up early 169 0.0406 0.062 0.00216
OV1002 carboplatin set 3 up late 163 0.577 0.112 0.059
OV1002 carboplatin set 4 down late 213 0.789 0.589 0.0935
OV1002 carboplatin/taxane set 1 up early 733 0.0936 0.152 0.463
OV1002 carboplatin/taxane set 2 down early 533 0.0257 0.809 0.0304
OV1002 carboplatin/taxane set 3 up late 958 0.263 0.008 6.48E05
OV1002 carboplatin/taxane set 4 down late 947 0.0288 0.0001 4.71E05
HOX424 carboplatin/taxane set 1 up late 148 0.0285 0.468 0.469
HOX424 carboplatin/taxane set 2 up late 27 0.869 0.065 0.532
HOX424 carboplatin/taxane set 3 down late 119 0.0398 0.0003 0.00126
HOX424 carboplatin/taxane set 4 down late 226 0.000463 0.00009 0.000102
KEGG apoptosis 88 0.00095 0.776 0.423
KEGG oocyte meiosis 114 0.647 0.00654 0.0203
KEGG progesterone-mediated oocyte maturation 87 0.886 0.0114 0.0847
KEGG p53 signalling pathway 69 0.372 0.0139 6.40E05
KEGG cell cycle 128 0.0453 0.138 0.443
OV1002 carboplatin/taxane cell cycle 51 0.0438 0.00814 0.00301
OV1002 carboplatin/taxane set 1 up early cell cycle 25 0.0272 0.00665 0.00683
KEGG glutathione metabolism 50 0.0259 0.00895 0.726
KEGG neurotrophin signalling pathway 126 0.0282 0.00133 7.54E06
KEGG b-alanine metabolism 22 0.0488 0.0414 0.000998
Abbreviations: KEGG¼Kyoto encyclopedia of genes and genomes; NA¼ not assigned; OS¼overall survival; PFS¼progression-free survival.
Significant P-values (Po0.05) are shown in bold.
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response (Wennemers et al, 2011), had the largest expression
increase upon both treatments. Heat shock proteins protect against
platinum drug activity, thus promoting resistance (Ren et al, 2008).
Several heat shock proteins, including hsp70s, were found down-
regulated in carboplatin–paclitaxel-treated OV1002 xenografts in
accordance to the chemoresponsiveness of this cell line.
In the slower growing HOX424, which displays reduced
platinum sensitivity, the RTV effect was smaller. Transcriptional
response to carboplatin was very limited, suggesting that
carboplatin is not internalised in sufficient quantities possibly
because of an effective transport mechanism potentially driven by
P-type ATPases or ABC transporters. Alternatively, HOX424 may
be capable of inactivating carboplatin in the cytoplasm by a
glutathione pathway-based mechanism. The response to the
combined treatment was exclusively late and contained apoptosis
and cell cycle regulators. The modest RTV effect may be attributed
to the activation of pro-apoptotic genes (Figure 3). Some, such as
FOSB, were not observed in OV1002. The MSH2 downregulation
may partly explain the lesser RTV effect in HOX424, as mismatch
repair pathway underexpression has been associated with carbo-
platin resistance (Fink et al, 1998). The effect diminished after day 7,
possibly because of the presence of efficient inherent oxidative
stress adaptations and failure to trigger apoptosis.
Taxanes, such as paclitaxel, act by stabilising microtubules,
thereby causing a G2–M arrest followed by apoptosis (Shah and
Schwartz, 2001). Gene expression differences between treatments
may be attributed to paclitaxel addition, yet this was not translated
in a dramatic RTV effect. The RTV reduction in carboplatin–
paclitaxel compared with carboplatin was significant only in
OV1002 day 7. There was substantial overlap between genes and
pathways targeted by carboplatin and paclitaxel; however, several
known paclitaxel targets, such as TRAF3 (Blagosklonny et al,
1997), were found in OV1002 and many tubulin isotypes in both
xenografts.
Both treatments triggered changes in cell cycle pathway at early
and late time points, but the response was more comprehensive in
carboplatin–paclitaxel treatment. A larger number of cell cycle
control genes were expressed late including cyclins, cyclin-
dependent kinases and CDCs, with more expressed after
carboplatin–paclitaxel treatment. Many genes affecting G2–M
checkpoint were upregulated late after carboplatin–paclitaxel
treatment, consistent with the known paclitaxel effect on inhibition
of microtubule spindle disassembly.
The two distinct treatment responses of the xenografts provide
a measure of interpatient gene expression diversity over time.
OV1002 demonstrated the largest RTV reduction and consis-
tently responded to treatment in early time points, whereas
HOX424 was growing slower and lacked a sustained RTV
reduction effect. The marked variation in the two cell lines may
be useful to assess patient responses to new treatment, to
investigate mechanisms of drug resistance and possibly to find
ways to circumvent it.
Late downregulated genes in both cell lines were associated with
prognosis in two clinical data sets. Consistent with their functions,
increased expression of SPRY1, CITED2, FZD6 and downregula-
tion of PPFIBP1 were associated with the good prognosis patient
clusters. Members of the SPRY family are MAPK inhibitors and
RAS antagonists, usually acting as tumour suppressors (Fong et al,
2006; Schaaf et al, 2010). CITED2 interferes with the binding of the
transcription factors HIF1a or STAT2 (Yanagie et al, 2009; Yoon
et al, 2011), whereas FZD6 is a negative regulator of the canonical
Wnt signalling pathway, acting as an inhibitor of oncogenic
transformation and cell proliferation (Golan et al, 2004). PPFIBP1
interacts with S100A4, a calcium-binding protein related to tumour
invasiveness (Kriajevska et al, 2002). Expression levels of
ALDH1A1, ALDH5A1, ALG13, TMEM106B, SPAG16 and
N4BP2L1 were also elevated in good prognosis clusters; however,
their involvement in tumourigenesis is not established. Interest-
ingly, elevated SPAG16 has been reported in various tumours
(Silina¸ et al, 2011), whereas N4BP2L1 maps in the region of BRCA2
(13q13.1). Downregulation of these genes coincides with the
gradual loss of platinum sensitivity, as seen in the diminishing
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Figure 4. Kaplan–Meier distributions of patient groups clustered according to gene set expression. The KEGG pathway-derived gene sets were
prognostic of overall survival in two independent clinical studies (Bild et al, 2006; Tothill et al, 2008). Genes from (A) cell cycle, (B) glutathione
metabolism, (C) neurotrophin signalling pathway and (D) b-alanine metabolism were overrepresented in the carboplatin–paclitaxel-treated
OV1002 xenografts. The complete cell cycle pathway (N¼ 128) gene set was significant in one independent data set, whereas the subset of genes
found significant in this study (N¼51) was prognostic in both data sets.
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RTV reduction effect after day 7, and may be driving the switch
from a responsive to a nonresponsive phenotype (Table 2).
Heatmaps in Supplementary Figure 1 indicate the potential value
of these genes as biomarkers of outcome.
Several overrepresented pathways identified from the xenografts
were found associated with prognosis in the clinical data sets,
including the neurotrophin signalling pathway overrepresented in
late downregulated genes from OV1002 carboplatin–paclitaxel-
treated xenografts. Neurotrophin factors 4/5 are expressed in breast
cancer and have been targeted to inhibit breast tumour growth
(Vanhecke et al, 2011). Neurotrophin plays a role in the early
development of follicles acting via TRKB receptors (Dorfman et al,
2011), and it is plausible that related pathways become dysregulated
during tumourigenesis and potentially have prognostic value.
Although the aim of this study is to characterise the dynamic
response to platinum drugs and taxanes, rather than assembling a
resistance or survival-associated gene signature, several genes from
these clusters are promising leads that warrant further investiga-
tion. The discovery of gene sets and pathways derived from the late
downregulated clusters that were associated with prognosis has
been possible only through a dynamic analysis of gene expression
over a period of several days. It would be interesting to explore
their expression patterns before and after treatment in patients or
in additional cell line xenografts.
In this study we demonstrate for the first time that genes
responding in a time-related manner to carboplatin–paclitaxel can
predict prognosis in primary tumours treated with these
chemotherapeutic drugs. Further clinical assessment in pre- and
post-treatment tumours from responding or resistant patients will
help determine which of those have the potential to be used as
predictors of response.
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